登录 | 注册    关注公众号  
微信公众号
搜索
 > 【SOST】

SOST信息

英文名称:Sclerostin
中文名称:硬骨素
靶点别称:Sclerostin,UNQ2976/PRO7455/PRO7476,SOST,Sclerosteosis,DAND6,SOST1,VBCH,CDD
上市药物数量:1
临床药物数量:3
最高研发阶段:批准上市

SOST产品列表

ACRO质量管理体系
 
评论(1)
SOT-H8245|Biotinylated Human SOST / Sclerostin Protein, His Tag, ultra sensitivity (primary amine labeling)
  1. 186XXXXXXX4
  2. 1人赞
  3. 通过sost要用来筛选噬菌体文库,并通过竞争elisa筛选得到与lrp6竞争的阳性克隆。实验数据很好,重复性也不错。大赞
  4. 2023-03-21
 

SOST分子别名

SOST,VBCH

SOST分子背景

Sclerostin (SOST) is also known as Sclerosteosis, VBCH, is a secreted glycoprotein with a signal peptide for secretion and a C-terminal cysteine knot-like (CTCK) domain and belongs to the Cerberus/DAN family of bone morphogenetic protein (BMP) antagonists. Sclerostin is produced by the osteocyte and has anti-anabolic effects on bone formation. More recently Sclerostin has been identified as binding to LRP5/6 receptors and inhibiting the Wnt signalling pathway. Wnt pathway inhibition under these circumstances is antagonistic to bone formation (meaning Sclerostin antagonizes bone formation). It has been shown that SOST binds BMP-5, -6, and -7 with high affinity and BMP-2 and -4 with low affinity. Sclerostin production by osteocytes is inhibited by parathyroid hormone, mechanical loading and cytokines including oncostatin M, cardiotrophin-1 and leukemia inhibitory factor. Sclerostin production is increased by calcitonin. Thus, osteoblast activity is self regulated by a negative feedback system. Mutations of Sclerostin is associated with the syndrome Sclerosteosis, and reduced sclerostin expression results in a milder form of the disorder called van Buchem disease.

SOST上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Romosozumab AMG-785; CDP-7851 批准上市 安进, 比利时联合化工集团 Evenity, EVENITY Japan 骨质疏松症 Amgen Inc 2019-01-08 代谢性骨病, 骨质疏松症, 绝经期后骨质疏松, 成骨不全, 骨损伤 详情

SOST临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Blosozumab LY-2541546; TST002; TST-002 临床一期 礼来制药 骨质疏松症, 绝经期后骨质疏松 详情
Resugosbart SHR-1222 临床一期 江苏恒瑞医药股份有限公司, 苏州盛迪亚生物医药有限公司, 上海恒瑞医药有限公司 骨质疏松症, 绝经期后骨质疏松 详情
Setrusumab UX143; NOV-3; MOR-05813; BPS-804 临床三期 Morphosys Ag, 诺华制药 骨质疏松症, 代谢性骨病, 低磷酸酯酶症, 成骨不全, 慢性肾功能不全 详情

消息提示

请输入您的联系方式,再点击提交!

确定